Program News
News and stories about the UNC Lineberger Bladder Cancer Center of Excellence
-
Bladder cancer: what patients need to know
Each year, nearly 75,000 people are diagnosed with bladder cancer. While more common in men over age 55, bladder cancer can—and does—affect women and men of all ages. Hear from our bladder cancer specialists to learn what newly diagnosed patients and their loved ones should know about bladder cancer.
-
Genetic analysis of the most common type of bladder cancer in patients with metastatic disease yields guidance on treatment options
A genomic study of more than 200 people with the most common type of bladder cancer that has spread could help guide how the cancer would respond to immunotherapy.
-
Urologic oncologist makes his mark through robotic surgery program
Marc Bjurlin, DO, MSc, FACOS, specializes in minimally invasive techniques in cancer surgery and brings his expertise to the single port robotic surgery program.
-
Chemotherapy plus immunotherapy before surgery is beneficial for invasive bladder cancer outcomes
Tracy Rose, MD, MPH, Matthew Milowsky, MD, and colleagues report that the regimen reduced the invasiveness of the cancer in 56% of patients in a phase II clinical trial.
-
Experimental drug that boosts immunotherapy shows promise in bladder cancer study
William Kim, MD, and colleagues have published findings that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission in laboratory models.
-
Patients with advanced bladder cancer could benefit from immunotherapy regardless of gene mutation status
Led by William Kim, MD, and colleagues, this research has important implications for patients who have not been offered immunotherapy because of their genetic profiles.
-
Patient a friend to others on bladder cancer journey
Over the years, Linda Willey has helped others going through cancer treatment. After treatment for her own cancer, she continues to connect with and support cancer patients.
-
Milowsky, Osterman published in the journal Cancer
Matthew Milowsky, MD, co-wrote an editorial on efforts to optimize a new precision medicine approach for treating metastatic urothelial carcinoma.